Form 4: Day One Biopharmaceuticals CEO Jeremy Bender Reports Stock Transactions

CEO Jeremy Bender reports acquisition and disposal of Day One Biopharmaceuticals stock, including transactions related to RSU settlements and tax liabilities.

Summary

• Jeremy Bender, CEO of Day One Biopharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• The report includes the acquisition of common stock through the vesting of Restricted Stock Units (RSUs) on February 15, 2025.
• Bender also disposed of 12,048 shares of common stock on February 18, 2025, at a price of $11.963 per share to cover tax liabilities related to RSU settlements.
• Following these transactions, Bender directly owns 128,015 shares of common stock.
• Bender also indirectly owns shares through various trusts, including The Jeremy Bender 2022 Grantor Retained Annuity Trust (162,762 shares), The Jeremy Bender 2023 Grantor Retained Annuity Trust (219,406 shares), The Melissa Bender 2022 Grantor Retained Annuity Trust (222,030 shares), The Melissa Bender 2023 Grantor Retained Annuity Trust (197,614 shares), and the Bender Revocable Trust (807,026 shares).
• The RSUs vest in quarterly installments, and do not expire, but may be canceled prior to the vesting date.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment about the company's performance.

Industry Context

Form 4 filings are standard practice for company insiders to report their transactions in company stock, providing transparency to investors.

Comparison to Industry Standards

• Tracking insider transactions is a common practice in financial analysis to gauge management's sentiment about the company's prospects.
• Comparing the volume and frequency of insider buying and selling activity to peers like Pfizer, Johnson & Johnson, and Novartis can provide insights into relative valuation and growth expectations.
• For example, if executives at Day One Biopharmaceuticals are consistently buying shares while peers are selling, it could signal stronger confidence in Day One's future performance.

Stakeholder Impact

• Shareholders are informed about the CEO's stock transactions, providing transparency.
• The transactions may have a minor impact on the stock price due to the sale of shares.

Key Dates

Keywords

Form 4, beneficial ownership, stock transactions, RSU, Jeremy Bender, Day One Biopharmaceuticals, DAWN, CEO